Clinical Trial

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-05; most recent amendment 2025-06-30.
Status change: Enrolling by Invitation → Recruiting 2025-03-01
Trial Details
NCT Number NCT06811844
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response, Chemotherapy
Enrollment 208 participants
Start Date 2025-02-25
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-01